Neurovasc Technologies Inc., of Laguna Hills, Calif., has entered a strategic partnership with the Wego Group that includes $34 million in funding to support the company’s product portfolio development and global clinical trial program. Specifically, the funding first will go toward studies of the company’s stent-retriever, designed to treat patients suffering an acute ischemic stroke, in markets such as Japan, the EU, U.S. and China.

LONDON – The COVID-19 epidemic has reached a “decisive point” as the number of new cases in the rest of the world exceeded the number of new cases in China, and seven countries reported infections for the first time.

BEIJING – Chinese biosimilar maker Bio-Thera Solutions Ltd., of Guangzhou, on Feb. 21 launched a pre-revenue listing on Shanghai’s STAR market to reap $241 million at a valuation of almost $2 billion.

LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from WHO Director General Tedros Adhanom Ghebreyesus.

LONDON – Six weeks on from the initial alert, “the window of opportunity” to control the COVID-19 epidemic is “narrowing,” according to the latest assessment from World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus.

HONG KONG – Beijing-headquartered Canbridge Pharmaceuticals Inc. has completed a $98 million series D financing round to target rare genetic diseases in China, and is considering an IPO after several rounds of financing to further pursue its goal.

BEIJING – Chinese biosimilar maker Bio-Thera Solutions Ltd., of Guangzhou, on Feb. 21 launched a pre-revenue listing on Shanghai’s STAR market, a Nasdaq-style tech board, to reap $241 million at a valuation of almost $2 billion. Its share price soared more than 83% during its first trading day.

BEIJING – Multiple China-based clinical trials have been put on hold as the country concentrates on its fight against COVID-19. To curb the spread of the novel coronavirus that has infected over 72,000 people and killed nearly 2,000, China has imposed travel and transport restrictions, making trips difficult or even impossible for patients and physicians.

The latest mutation to the coronavirus, dubbed COVID-19, has sparked a reaction by many national governments, but the expense associated with development of vaccines and diagnostics is considerable.